Literature DB >> 20127295

Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.

Elizabeth J Rahn1, Alexander M Zvonok, Alexandros Makriyannis, Andrea G Hohmann.   

Abstract

Cannabinoid CB(2) receptors represent a therapeutic target that circumvents unwanted central side effects (e.g., psychoactivity and/or addiction) associated with activation of CB(1) receptors. One of the primary investigative tools used to study functions of the CB(2) receptor is the aminoalkylindole (R,S)-AM1241. However, (R,S)-AM1241 has been described as an atypical CB(2) agonist which produces antinociception mediated indirectly by opioid receptors. (R,S)-AM1241 and its enantiomers, (R)-AM1241 and (S)-AM1241, were evaluated for antinociception in response to thermal (Hargreaves) and mechanical (von Frey) stimulation. Pharmacological specificity was established using antagonists for CB(1) (rimonabant [SR141716]) and CB(2) (SR144528). The opioid antagonist naloxone was administered locally in the paw or systemically to evaluate the contribution of opioid receptors to CB(2)-mediated antinociception produced by (R,S)-AM1241, (R)-AM1241, and (S)-AM1241. Comparisons were made with the opioid analgesic morphine. (R,S)-AM1241, (R)-AM1241, and (S)-AM1241 (0.033-10 mg/kg i.p.) produced antinociception to thermal, but not mechanical, stimulation of the hindpaw in naive rats. Antinociception produced by (R,S)-AM1241 and (S)-AM1241 exhibited an inverted U-shaped dose response curve. (R)-AM1241 produced greater antinociception than either (S)-AM1241 or (R,S)-AM1241 at the lowest (0.033 and 0.1 mg/kg i.p.) and highest (10 mg/kg i.p.) doses. Similar levels of antinociception were observed at intermediate doses. (R,S)-AM1241, (R)-AM1241, and (S)-AM1241 each produced CB(2)-mediated antinociception that was blocked by SR144528 but not by rimonabant. Local and systemic naloxone blocked morphine-induced antinociception but did not block antinociceptive effects of (R,S)-AM1241, (R)-AM1241, or (S)-AM1241. The antinociceptive effects of the CB(2)-selective cannabinoid (R,S)-AM1241 and its enantiomers, (R)-AM1241 and (S)-AM1241, are not dependent upon opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127295      PMCID: PMC2844508          DOI: 10.1208/s12248-009-9170-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  35 in total

1.  CB2 cannabinoid receptor-mediated peripheral antinociception.

Authors:  T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

2.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.

Authors:  L Hanus; A Breuer; S Tchilibon; S Shiloah; D Goldenberg; M Horowitz; R G Pertwee; R A Ross; R Mechoulam; E Fride
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

3.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.

Authors:  K Hargreaves; R Dubner; F Brown; C Flores; J Joris
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

4.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

5.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS.

Authors:  Mohab M Ibrahim; Hongfeng Deng; Alexander Zvonok; Debra A Cockayne; Joyce Kwan; Heriberto P Mata; Todd W Vanderah; Josephine Lai; Frank Porreca; Alexandros Makriyannis; T Philip Malan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

Review 6.  Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Authors:  Elizabeth J Rahn; Andrea G Hohmann
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

7.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

8.  Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.

Authors:  Ji Zhang; Cyrla Hoffert; Huy Khang Vu; Thierry Groblewski; Sultan Ahmad; Dajan O'Donnell
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

Review 9.  Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives.

Authors:  Andrea G Hohmann
Journal:  Chem Phys Lipids       Date:  2002-12-31       Impact factor: 3.329

10.  Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.

Authors:  A G Nackley; A Makriyannis; A G Hohmann
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  12 in total

1.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

2.  2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective.

Authors:  Alexandros Makriyannis
Journal:  J Med Chem       Date:  2014-05-01       Impact factor: 7.446

Review 3.  Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Authors:  Srikrishnan Mallipeddi; David R Janero; Nikolai Zvonok; Alexandros Makriyannis
Journal:  Biochem Pharmacol       Date:  2016-11-24       Impact factor: 5.858

4.  Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.

Authors:  Ai-Ling Li; Lawrence M Carey; Ken Mackie; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2017-06-07       Impact factor: 4.030

5.  The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.

Authors:  Steven G Kinsey; Anu Mahadevan; Bingjun Zhao; Hang Sun; Pattipati S Naidu; Raj K Razdan; Dana E Selley; M Imad Damaj; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2010-09-16       Impact factor: 5.250

6.  Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.

Authors:  Elizabeth J Rahn; Ganesh A Thakur; Jodi Anne T Wood; Alexander M Zvonok; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Pharmacol Biochem Behav       Date:  2011-03-05       Impact factor: 3.533

7.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

8.  Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist.

Authors:  Jodianne T Wood; Dustin M Smith; David R Janero; Alexander M Zvonok; Alexandros Makriyannis
Journal:  Life Sci       Date:  2012-06-28       Impact factor: 5.037

9.  Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.

Authors:  Josée Guindon; Yvonne Lai; Sara M Takacs; Heather B Bradshaw; Andrea G Hohmann
Journal:  Pharmacol Res       Date:  2012-11-02       Impact factor: 7.658

Review 10.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.